Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis

Shinji Matsunaga, Taro Kishi, Peter Annas, Hans Basun, Harald Hampel, Nakao Iwata

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

Background: This is the first meta-analysis of randomized placebo-controlled trials testing lithium as a treatment for patients with Alzheimer's disease (AD) and individuals with mild cognitive impairment (MCI). Methods: The primary outcome measure was efficacy on cognitive performance as measured through the Alzheimer's Disease Assessment Scale cognitive subscale or the Mini-Mental State Examination. Other outcome measures were drug discontinuation rate, individual side effects, and biological markers (phosphorylated tau 181, total tau, and amyloid-β42) in cerebrospinal fluid (CSF). Results: Three clinical trials including 232 participants that met the study's inclusion criteria were identified. Lithium significantly decreased cognitive decline as compared to placebo (standardized mean difference = -0.41, 95% confidence interval = -0.81 to -0.02, p = 0.04, I2 = 47%, 3 studies, n = 199). There were no significant differences in the rate of attrition, discontinuation due to all causes or adverse events, or CSF biomarkers between treatment groups. Conclusions: The results indicate that lithium treatment may have beneficial effects on cognitive performance in subjects with MCI and AD dementia.

Original languageEnglish
Pages (from-to)403-410
Number of pages8
JournalJournal of Alzheimer's Disease
Volume48
Issue number2
DOIs
Publication statusPublished - 09-09-2015

Fingerprint

Lithium
Meta-Analysis
Alzheimer Disease
Cerebrospinal Fluid
Biomarkers
Placebos
Outcome Assessment (Health Care)
Therapeutics
Amyloid
Randomized Controlled Trials
Clinical Trials
Confidence Intervals
Pharmaceutical Preparations
Cognitive Dysfunction

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Matsunaga, Shinji ; Kishi, Taro ; Annas, Peter ; Basun, Hans ; Hampel, Harald ; Iwata, Nakao. / Lithium as a Treatment for Alzheimer's Disease : A Systematic Review and Meta-Analysis. In: Journal of Alzheimer's Disease. 2015 ; Vol. 48, No. 2. pp. 403-410.
@article{77af7cb215b645399501ddfff6a561f1,
title = "Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis",
abstract = "Background: This is the first meta-analysis of randomized placebo-controlled trials testing lithium as a treatment for patients with Alzheimer's disease (AD) and individuals with mild cognitive impairment (MCI). Methods: The primary outcome measure was efficacy on cognitive performance as measured through the Alzheimer's Disease Assessment Scale cognitive subscale or the Mini-Mental State Examination. Other outcome measures were drug discontinuation rate, individual side effects, and biological markers (phosphorylated tau 181, total tau, and amyloid-β42) in cerebrospinal fluid (CSF). Results: Three clinical trials including 232 participants that met the study's inclusion criteria were identified. Lithium significantly decreased cognitive decline as compared to placebo (standardized mean difference = -0.41, 95{\%} confidence interval = -0.81 to -0.02, p = 0.04, I2 = 47{\%}, 3 studies, n = 199). There were no significant differences in the rate of attrition, discontinuation due to all causes or adverse events, or CSF biomarkers between treatment groups. Conclusions: The results indicate that lithium treatment may have beneficial effects on cognitive performance in subjects with MCI and AD dementia.",
author = "Shinji Matsunaga and Taro Kishi and Peter Annas and Hans Basun and Harald Hampel and Nakao Iwata",
year = "2015",
month = "9",
day = "9",
doi = "10.3233/JAD-150437",
language = "English",
volume = "48",
pages = "403--410",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

Lithium as a Treatment for Alzheimer's Disease : A Systematic Review and Meta-Analysis. / Matsunaga, Shinji; Kishi, Taro; Annas, Peter; Basun, Hans; Hampel, Harald; Iwata, Nakao.

In: Journal of Alzheimer's Disease, Vol. 48, No. 2, 09.09.2015, p. 403-410.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Lithium as a Treatment for Alzheimer's Disease

T2 - A Systematic Review and Meta-Analysis

AU - Matsunaga, Shinji

AU - Kishi, Taro

AU - Annas, Peter

AU - Basun, Hans

AU - Hampel, Harald

AU - Iwata, Nakao

PY - 2015/9/9

Y1 - 2015/9/9

N2 - Background: This is the first meta-analysis of randomized placebo-controlled trials testing lithium as a treatment for patients with Alzheimer's disease (AD) and individuals with mild cognitive impairment (MCI). Methods: The primary outcome measure was efficacy on cognitive performance as measured through the Alzheimer's Disease Assessment Scale cognitive subscale or the Mini-Mental State Examination. Other outcome measures were drug discontinuation rate, individual side effects, and biological markers (phosphorylated tau 181, total tau, and amyloid-β42) in cerebrospinal fluid (CSF). Results: Three clinical trials including 232 participants that met the study's inclusion criteria were identified. Lithium significantly decreased cognitive decline as compared to placebo (standardized mean difference = -0.41, 95% confidence interval = -0.81 to -0.02, p = 0.04, I2 = 47%, 3 studies, n = 199). There were no significant differences in the rate of attrition, discontinuation due to all causes or adverse events, or CSF biomarkers between treatment groups. Conclusions: The results indicate that lithium treatment may have beneficial effects on cognitive performance in subjects with MCI and AD dementia.

AB - Background: This is the first meta-analysis of randomized placebo-controlled trials testing lithium as a treatment for patients with Alzheimer's disease (AD) and individuals with mild cognitive impairment (MCI). Methods: The primary outcome measure was efficacy on cognitive performance as measured through the Alzheimer's Disease Assessment Scale cognitive subscale or the Mini-Mental State Examination. Other outcome measures were drug discontinuation rate, individual side effects, and biological markers (phosphorylated tau 181, total tau, and amyloid-β42) in cerebrospinal fluid (CSF). Results: Three clinical trials including 232 participants that met the study's inclusion criteria were identified. Lithium significantly decreased cognitive decline as compared to placebo (standardized mean difference = -0.41, 95% confidence interval = -0.81 to -0.02, p = 0.04, I2 = 47%, 3 studies, n = 199). There were no significant differences in the rate of attrition, discontinuation due to all causes or adverse events, or CSF biomarkers between treatment groups. Conclusions: The results indicate that lithium treatment may have beneficial effects on cognitive performance in subjects with MCI and AD dementia.

UR - http://www.scopus.com/inward/record.url?scp=84941278298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941278298&partnerID=8YFLogxK

U2 - 10.3233/JAD-150437

DO - 10.3233/JAD-150437

M3 - Review article

C2 - 26402004

AN - SCOPUS:84941278298

VL - 48

SP - 403

EP - 410

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -